Press Releases

Mernova Medicinal Inc. secures licensing and supply agreement with Khalifa Kush Enterprises

29 Jan 2021 | by: Patricia Miller

Value – up to AUD$10.25m

  • HighlightsKhalifa Kush Enterprises (KKE) is the Canadian arm of Wiz Khalifa’s global cannabis company
  • Deal is worth up to $10.25m for Creso
  • Mernova and KKE will collaborate to cultivate and distribute Khalifa Kush branded cannabis products from KKE’s leading plant genetics in Canada
  • Mernova to produce approximately 50kg per month and receive C$3.60/g from KKE
  • First cultivation set to commence within approx. 60 days with rapid scale up expected.
  • Agreement to considerably increase Creso’s growing revenue streams – initial sales earmarked to commence for end of 1q.

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that it’s wholly-owned Canadian subsidiary Mernova Medicinal Inc. (“Mernova”) has signed a non-binding term sheet with Khalifa Kush Enterprises Canada ULC (“KKE”) to cultivate and distribute dried cannabis flower sourced from KKE product genetics to the Canadian market.

Khalifa Kush Enterprises was founded in 2018 and is the first expansion of Khalifa Kush outside of the US. Khalifa Kush products were first commercialised in the US in 2015 by multi-platinum, Grammy Award and Golden Global nominated recording artist Wiz Khalifa and his long time business associates Will Dzombak (CEO, Taylor Gang), Tim Hunkele (Vice President, Taylor Gang) and Constance Schwartz (Founder and CEO, SMAC Entertainment).

Khalifa Kush has achieved major success in the US market, following the creation of high quality and sought-after products which are currently being sold in Nevada and Arizona.

Mernova Managing Director, Jack Yu said:

“This agreement is a signigicant achievement for Mernova and Creso Pharma. It follows considerable due diligence from Khalifa Kush on the Company’s production facilities and manufacturing capabilities and highlights the integrity and trustworthiness of our operations.

We expect that sales of KKE products will add considerably to our growing revenue streams and unlock a number of new provinces and opportunities for Mernova. We will work closely with KKE to ensure the product is of a superior quality and well received by customers.

We have a number of potential sales channels already earmarked and look forward to providing shareholders on progress over the coming months.”

Under the agreement, Mernova and KKE will collaborate to cultivate and distribute Khalifa Kush dried cannabis flower products sourced from leading KKE product genetics for the Canadian market. Mernova will be charged with the cultivation, harvesting and packaging of the products, which will be undertaken at its fully licenced 24,000 square foot facility in Nova Scotia.

Creso will dedicate XX flower rooms to the new products and produce a minimum of 50kgs of product per month. In return, KKE will pay Mernova and Creso Pharma C$3.60 per gram of product. This is expected to significantly increase the Company’s revenue profile. Both parties will also work together to increase harvest and cultivation volumes over the next twelve months.

Mernova and Creso will also retain a first right of refusal to cultivate and sell other KKE cannabis products including edibles, vapes and concentrates on reasonable commercial terms in any jurisdiction outside of the US and Canada.

This agreement is a major achievement for Creso Pharma and highlights its ability to manufacture product at the highest standard for the Canadian market. The Company expects sales of KKE products to materially add to its revenue profile. First cultivation is expected in q1 2021 and management looks forward to providing ongoing updates to shareholder on progress.

Authority and Contact Details
This announcement has been authorised for release by the Creso Board

For further information, please contact:

Investor Enquiries                                                            
EverBlu Capital                                                     
E: [email protected]                                           
P: +61 2 8249 0000       

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.  To learn more please visit:

Forward Looking statements 

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by CRESO PHARMA LTD. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of five hundred thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above., Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

  • Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Digitonic Ltd, the owner of, has been paid for the production this piece by the company or companies mentioned above.

More News & Analysis